NTRA - Natera, Inc.
IEX Last Trade
162.35
27.170 16.735%
Share volume: 0
Last Updated: Tue 24 Dec 2024 06:01:33 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
35.29%
PREVIOUS CLOSE
CHG
CHG%
$135.18
27.17
20.10%
Fundamental analysis
24%
Profitability
25%
Dept financing
14%
Liquidity
67%
Performance
15%
Performance
5 Days
0.32%
1 Month
-1.22%
3 Months
29.92%
6 Months
45.84%
1 Year
166.91%
2 Year
302.75%
Key data
Stock price
$162.35
DAY RANGE
$135.18 - $162.02
52 WEEK RANGE
$60.00 - $175.63
52 WEEK CHANGE
$165.26
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
Company detail
CEO: Stephen Chapman
Region: US
Website: natera.com
Employees: 3,020
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: natera.com
Employees: 3,020
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage.
Recent news